AI-driven multimodal algorithm predicts immunotherapy and targeted therapy outcomes in clear cell renal cell carcinoma Journal Article


Authors: Stupichev, D.; Miheecheva, N.; Postovalova, E.; Lyu, Y.; Ramachandran, A.; Galkin, I.; Khegai, G.; Perevoshchikova, K.; Love, A.; Menshikova, S.
Article Title: AI-driven multimodal algorithm predicts immunotherapy and targeted therapy outcomes in clear cell renal cell carcinoma
Abstract: Treatment for metastatic clear cell renal cell carcinoma (ccRCC) has dramatically advanced with tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor (ICI) administration. However, most patients eventually succumb to their disease, and toxicities associated with individual treatment modalities are significant. Multiple single-modality transcriptomic signatures have been developed to predict treatment response, yielding insightful yet inconsistent results when applied to independent cohorts. By unifying transcriptomic data from 14 cohorts (total n = 3,621), we present harmonized immune tumor microenvironment (HiTME) ccRCC subtypes validated with spatial proteomics. This AI-based multimodal approach integrates genomic, transcriptomic, and tumor microenvironment (TME) features for ICI and TKI therapy response prediction. © 2025 Elsevier B.V., All rights reserved.
Keywords: tyrosine kinase inhibitors; clear cell renal cell carcinoma; tumor microenvironment; tumor heterogeneity; spatial heterogeneity; predictive biomarkers; immune checkpoint inhibitors; multiplex immunofluorescence; single-cell proteogenomics; artificial intelligence-based predictive modeling
Journal Title: Cell Reports Medicine
Volume: 6
Issue: 8
ISSN: 26663791
Publisher: Elsevier B.V.  
Date Published: 2025-01-01
Start Page: 102299
Language: English
DOI: 10.1016/j.xcrm.2025.102299
PROVIDER: scopus
DOI/URL:
Notes: Article -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics